<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318123</url>
  </required_header>
  <id_info>
    <org_study_id>LAKE</org_study_id>
    <secondary_id>2004-001282-18</secondary_id>
    <nct_id>NCT00318123</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients</brief_title>
  <official_title>Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the therapeutic equivalence between the two arms of treatment in virological and
      immunological response after 48 weeks and to evaluate the presence of side effects during the
      follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of the highly active antiretroviral treatment (HAART) has been demonstrated in
      several clinical trials. Even so, a substantial proportion of patients do not manage to
      maintain correct viral suppression in daily clinical practice.

      Adherence to HAART treatment is critical to obtain lasting viral suppression. Thus, factors
      that are related to adherence such as high pill load or takes, the complexity of the
      antiretroviral system, tolerability and food restrictions may have an effect on viral
      replication.

      It has been demonstrated that simpler regimens with a scant number of tablets, without food
      restrictions and with a single take a day are safe, efficacious and that adherence improves.

      The combination of abacavir 600 mg + lamivudine 300 mg QD in a single tablet is a novel
      dosage that may help increase treatment adherence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the virological response over the 48 weeks of the study.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunological efficacy (changes in CD4 and CD8 counts) of the combination studied over the follow-up period.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact of treatment on the lipid profile.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the tolerance and safety of the combination of Efavirenz + lamivudine + abacavir given once daily over the 48-week treatment period.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate treatment adherence (assessed by a self-reported questionnaire and with graduated satisfaction scales) and patient quality of life (assessed by means of the MOS-HIV questionnaire).</measure>
    <time_frame>At 12, 24, 36 and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyse the mutations that appear in patients that present virological failure.</measure>
    <time_frame>When there is a virological failure.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kivexa</intervention_name>
    <description>abacavir 600mg + lamivudine 300mg in one tablet QD</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt; 18 years.

          2. HIV-1 infected patients.

          3. Naive to antiretroviral treatment.

          4. Candidate patient for initiating antiretroviral treatment*.

          5. Subject able to follow the treatment period.

          6. Signature of the informed consent.

          7. Women may not be fertile age (defined as at least one year from menopause or
             undergoing any surgical sterilisation technique), or must undertake to use two
             contraceptive methods during the study, one of them at least being a barrier method.

        Exclusion Criteria:

          1. Hepatic tests &gt; 5 times above normality.

          2. Pregnancy or breastfeeding.

          3. Treatment for opportunistic infections or neoplasms associated with the stable HIV
             over the last 6 weeks.

          4. Suspected or documented resistance to any of the investigational drugs.

          5. Known allergic hypersensitivity to any of the investigational drugs or any similar
             drug.

          6. Subjects with abusive consumption of alcohol or illegal drugs.

          7. Patients participating in another clinical trial.

          8. Terminal renal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLuita contra la Sida Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Infections and Tropical Diseases University of Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Generall de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Alacant</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Sra del Rosell</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Asturias</city>
        <state>Oviedo</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>January 25, 2008</last_update_submitted>
  <last_update_submitted_qc>January 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lluita Sida Foundation</name_title>
    <organization>Lluita Sida Foundation</organization>
  </responsible_party>
  <keyword>Simplification therapy</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Virological effectiveness</keyword>
  <keyword>Immunological effectiveness</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

